The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?

Launched by UNIVERSITY HOSPITAL HEIDELBERG · May 13, 2022

Keywords

ClinConnect Summary

The CyberChallenge Trial is a research study looking at how well a treatment called Cyberknife radiosurgery works for patients with multiple brain metastases, which are cancerous spots that have spread to the brain. This trial aims to compare the effectiveness and side effects of Cyberknife radiosurgery to a different treatment called whole-brain radiotherapy. The goal is to find out if Cyberknife, which usually requires fewer treatment sessions, can be just as effective but with less impact on patients’ health and quality of life.

To participate in this trial, patients should be 18 years or older and have a confirmed diagnosis of cancer with 4 to 15 suspected tumors in the brain. They also need to be able to understand the study and provide written consent. However, some individuals may not qualify, including those with certain types of cancer or those who have had previous brain radiation. Participants can expect to receive the treatment and be monitored closely throughout the study to see how well it works and what side effects they may experience. If you or a loved one has advanced cancer with brain metastases, this trial may offer a new option for treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologically confirmed malignant illness
• • 4-15 suspect intracranial lesions, taking into consideration all available MRI series
• • age ≥ 18 years of age
• • For women with childbearing potential, (and men) adequate contraception.
• • Ability of subject to understand character and individual consequences of the clinical trial
• • Written informed consent (must be available before enrolment in the trial)
• Exclusion Criteria:
• • Refusal of the patients to take part in the study
• • Inability to tolerate irradiation consistent with the protocol
• • Small-cell lung cancer (SCLC) or lymphoma as primary malignant illness
• • \>15 suspect intracranial lesions, taking into consideration all available MRI series
• • leptomeningeal disease
• • Previous radiotherapy of the brain
• • Patients who have not yet recovered from acute high-grade toxicities of prior therapies
• • Pregnant or lactating women
• • Participation in another competing clinical study or observation period of competing trials, respectively
• • MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)